Q-omics provides the consensus-scored TMEM209 profile across patient tissues and cancer cell-line models. TMEM209 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM209 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM209 protein abundance shows 27,042 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where TMEM209 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM209 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM209 survival associations across molecular data types. TMEM209 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM209 RNA expression–survival associations across cancer types. High TMEM209 expression shows unfavorable associations in UVM, KICH, LGG, CESC and LIHC, but favorable associations in LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM209 RNA expression.
This table summarizes TMEM209 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM209. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM209 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, KIRP, LUAD and LIHC. The HNSC box plot shows higher TMEM209 RNA expression in tumor versus normal tissue (log2 FC = +1.265, t-test p < 0.001).
This table shows molecular features associated with TMEM209 in patient tissues and cancer cell lines. In patient samples, TMEM209 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM209 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
